Cardinal Health (CAH) Q4 2026 Earnings Call Transcript
Cardinal Health (CAH) reported Q4 2026 revenue of $63.7B, up 6%, driven by Pharmaceutical and Specialty Solutions. Non-GAAP EPS was $2.91, up 40%. Fiscal 2027 guidance includes 3-5% pharma revenue growth and 8-11% profit growth. The company plans $1B in share repurchases and increased its authorization to $6.4B. Management cited risks from geopolitical instability and IRA price changes.
How this was made
The 30-second read
Why it matters
Traders can update models immediately using the quantified fiscal 2027 EPS and segment profit/revenue ranges, and stress-test downside scenarios around IRA pricing annualization and potential prolonged geopolitical instability affecting GMPD margins.
Market read
Fresh fiscal 2027 guidance and a larger buyback authorization are likely to drive near-term estimate revisions and positioning, with clear margin risks from IRA pricing and tariff/geopolitical factors.
What to watch
GMPD profit includes a one-time $100 million net operating benefit from IEEPA tariff refunds; investors may need to separate recurring improvement from refund-driven effects when modeling sustainability.
Background
Cardinal Health reported Q4 fiscal 2026 results and provided detailed fiscal 2027 guidance across Pharmaceutical and Specialty Solutions, GMPD, and Other Growth Businesses, alongside capital allocation updates.
Ticker impact
Cardinal Health guided fiscal 2027 EPS to $12.40 to $12.60 and Pharma profit to 8% to 11% growth, plus $1B+ buyback plan.
Likely near-term positive bias if investors view the $12.40 to $12.60 EPS range and $5B repurchase authorization as credible, but with sensitivity to GMPD profit guide risk from prolonged Iran conflicts and IRA price annualization.
This is a primary earnings call transcript with quantified fiscal 2027 guidance, segment profit drivers, and explicit risk framing (GMPD lower end if Iran conflicts persist; Pharma headwinds from annualization of IRA price changes).
Market effects
Reinforces demand strength in Pharmaceutical and Specialty Solutions tied to GLP-1 growth, while highlighting distribution margin sensitivity to tariffs and geopolitical disruptions.
Tariff refund repayments and IEEPA-related dynamics can affect US healthcare logistics economics and margin expectations.
Geopolitical risk (Iran conflict duration) is explicitly linked to GMPD profit guide range, which can spill into broader healthcare distribution risk premia.
Counterpoint
The guidance may embed optimistic assumptions on tariff offsets and specialty volume strength, so the risk is a wider-than-expected spread between the high and low ends of profit guidance.
Key entities
- companyCardinal Health, Inc.
Provided Q4 fiscal 2026 results and fiscal 2027 guidance, including EPS range, segment profit outlook, and an increased share repurchase authorization.
- executiveJason Hollar
CEO who discussed market coverage and integration progress, including Advanced Diabetes Supply and Solaris contribution expectations.
- executiveAaron Alt
CFO who quantified guidance drivers and explicitly flagged GMPD downside risk if Iran conflicts prove protracted.
